Dr Lal PathLabs shares soar 8% after Q1 earnings beat estimates. What Nomura, Nuvama, other brokerages are saying?

Dr Lal PathLabs shares surged after a strong Q1FY27 earnings beat, driven by higher realisations and price hikes. Brokerages including Nomura, Nuvama and JM Financial raised target prices, citing robust growth outlook, network expansion and improving margins, with continued momentum expected from diagnostics demand and strategic investments.